Cyclacel Pharmaceuticals Announces Agreement for 3.1 Million Investment by David Lazar as Interim CEO
| CYCC Stock | USD 0.41 0.04 8.89% |
About 62% of Cyclacel Pharmaceuticals' investor base is looking to short. The analysis of the overall investor sentiment regarding Cyclacel Pharmaceuticals suggests that many traders are alarmed. The current market sentiment, together with Cyclacel Pharmaceuticals' historical and current headlines, can help investors time the market. In addition, many technical investors use Cyclacel Pharmaceuticals stock news signals to limit their universe of possible portfolio assets.
Cyclacel |
Cyclacel Pharmaceuticals, Inc. has revealed the execution of a Securities Purchase Agreement with investor David Lazar, marking a significant move for the pharmaceutical company. The agreement, dated January 2, 2025, entails Lazar purchasing 1,000,000 shares of Series C Convertible Preferred Stock and 2,100,000 shares of Series D Convertible Preferred
Read at thelincolnianonline.com
 |
Cyclacel Pharmaceuticals Fundamental Analysis
We analyze Cyclacel Pharmaceuticals' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Cyclacel Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Cyclacel Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Earnings Per Share
Earnings Per Share Comparative Analysis
Cyclacel Pharmaceuticals is currently under evaluation in earnings per share category among its peers. Earnings per Share (EPS) denotes the portion of a company's earnings that is allocated to each share of common stock. To calculate Earnings per Share investors will need to take a company's net income, subtract any dividends for preferred stock, and divide it by the number of average outstanding shares. EPS is usually presented in two different ways: basic and diluted. Fully diluted Earnings per Share takes into account effects of warrants, options, and convertible securities and is generally viewed by analysts as a more accurate measure.
Cyclacel Pharmaceuticals Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Cyclacel Pharmaceuticals stock to make a market-neutral strategy. Peer analysis of Cyclacel Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Cyclacel Pharmaceuticals by comparing valuation metrics with similar companies.
Peers
Cyclacel Pharmaceuticals Related Equities
| TPST | Tempest Therapeutics | 10.47 | ||||
| RZLT | Rezolute | 4.22 | ||||
| AKTX | Akari Therapeutics | 2.17 | ||||
| MBRX | Moleculin Biotech | 1.13 | ||||
| OVID | Ovid Therapeutics | 1.05 | ||||
| XOMAO | XOMA | 0.32 | ||||
| ASMB | Assembly Biosciences | 0.12 | ||||
| PULM | Pulmatrix | 0.48 | ||||
| SPRO | Spero Therapeutics | 2.78 | ||||
| IKNA | Ikena Oncology | 3.01 | ||||
| NXTC | NextCure | 3.26 | ||||
| PTIX | Protagenic Therapeutics | 3.39 | ||||
| CNTB | Connect Biopharma | 3.45 | ||||
| EWTX | Edgewise Therapeutics | 4.37 | ||||
| CTMX | CytomX Therapeutics | 10.53 |
Complementary Tools for Cyclacel Stock analysis
When running Cyclacel Pharmaceuticals' price analysis, check to measure Cyclacel Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cyclacel Pharmaceuticals is operating at the current time. Most of Cyclacel Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Cyclacel Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cyclacel Pharmaceuticals' price. Additionally, you may evaluate how the addition of Cyclacel Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences |